Sparks - Cereno Scientific

Cereno Scientific has announced encouraging new preclinical results for CS014, its novel histone deacetylase (HDACi) inhibitor. CS014, together with lead asset CS1, are from the company’s HDACi program, which aims to leverage the principles of epigenetic modulation to develop disease-modifying therapies for cardiovascular diseases. The new CS014 data come from a well-established model of pulmonary arterial hypertension (PAH), and demonstrate a robust, dose-dependent reversal of pulmonary vascular remodelling, inducing statistically significant reductions in small artery vessel occlusion, plexiform lesions and small vessel related fibrosis. Collectively, the results highlight a new opportunity for CS014, offering the potential for disease-modification in PAH and related pulmonary vascular diseases.

CS014 is already in the clinical stages of development as a potential treatment for thrombosis prevention without increased risk of bleeding. It entered into a Phase I trial in June 2024 and initial data are expected from mid-2025.